Agenus Inc. (Nasdaq: AGEN) today
published a new blog post on The Chairman's Blog, written by the
company's Chairman and CEO, Dr. Garo Armen. TheChairmansBlog.com is
an exclusive online media publication that enables key executive
officers a unique platform to share insights about their company and
Chairman and CEO, Dr. Garo Armen, writes about GSK's newly
announced Phase 3 data for their RTS,S malaria vaccine candidate
containing Agenus' QS-21 Stimulon adjuvant. He reflects on the
companies' collaboration in their fight against malaria and results
from additional QS-21-containing programs he expects to see in the
near future. Read the full blog post on TheChairmansBlog.com
Agenus Inc. is a biotechnology company
working to develop treatments for cancers and infectious diseases.
The company is focused on immunotherapeutic products based on strong
platform technologies with multiple product candidates advancing
through the clinic, including several product candidates that have
advanced into late-stage clinical trials through corporate partners.
For more information, please visit http://www.agenusbio.com/.
an exclusive, online media publication where publically and
privatively held firms alike share insights about their companies and
industries. TheChairmansBlog.com enables upper tier management to
discuss issues that are of importance to their stakeholders,
shareholders, and interested parties in an informal environment. In
addition to management`s insightful blog posts, TheChairmansBlog.com
staff and aggregate partners contribute articles on finance,
technology, health, and energy while providing updated market trends,
news, and information.
Leave a comment...